|
Toggle Summary
March 12, 2020
|
MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT
WALTHAM, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a sharp reduction
|
MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT
|
|
Toggle Summary
March 9, 2020
|
Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass. , March 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical
|
Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
|
|
Toggle Summary
March 2, 2020
|
Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
Management to host conference call WALTHAM, Mass. , March 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
|
|
Toggle Summary
February 28, 2020
|
Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia
Breakfast meeting to be held on Friday, March 6, 2020 in New York WALTHAM, Mass. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central
|
Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
February 5, 2020
|
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Data readout expected in the second quarter of 2020 WALTHAM, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central
|
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
January 6, 2020
|
Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Top-line results expected in the second quarter of 2020 WALTHAM, Mass. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central
|
Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
December 18, 2019
|
Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass. , Dec.
|
Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder
|
|
Toggle Summary
November 14, 2019
|
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
WALTHAM, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies London
|
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
|
|
Toggle Summary
November 4, 2019
|
Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the
|
Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
|
|
Toggle Summary
October 28, 2019
|
Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
Management to host conference call WALTHAM, Mass. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
|
